echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Hydroxychloroquine and Covid-19: The never-ending story

    Hydroxychloroquine and Covid-19: The never-ending story

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), also known as COVID-19, has caused a pandemic that has rapidly spread across the world and has caused great public health concer.


    Studies have indirectly investigated the efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19 by determining the prevalence of COVID-19 in malaria-endemic and non-pandemic countri.


    Materials and methods:

    RESULTS: A total of 09 published articles were identified: 03 clinical trials with a sample size of 150; 03 in vitro studies and 03 expert consensus repor.


    result:

    Hydroxychloroquine and Chloroquine SARS-CoV-2 (COVID-19) Clinical Studies:

    Hydroxychloroquine and Chloroquine SARS-CoV-2 (COVID-19) Clinical Studies:

    Conclusion: Both chloroquine and hydroxychloroquine have antiviral properties in vit.


    in conclusion:

    What happened next, however, was an unfortunate comedy of errors, wasting resources and opportunities to find an effective cu.


    Hundreds of clinical trials were launched in spring 2020 to evaluate whether hydroxychloroquine can prevent or treat COVID-1 Based on publicly available data, 247 such trials were register.


    Like dozens of previously published small trials, it failed to demonstrate any benefit of hydroxychloroquine in preventing the progression of COVID-19 in outpatients initially with mild COVID-1

    With dozens of trials published, hydroxychloroquine is finally shut down for COVID-1 But it would be remiss not to draw some lessons for future epidemics and general clinical scien.


    Don’t put the cart before the horse

    Don’t put the cart before the horse

    While slow and arduous, the gradual progression of candidate therapies from in vitro effects to animal models to expanding clinical trials is critical to avoid mis-prioritization of drugs that have little prospect of success but risk diverting scarce resources and exposing patients to potential ha.


    Enthusiasm for hydroxychloroquine accelerated after a study showed it could block SARS-Cov-2 infection in cells derived from monkey kidne.


    Science should go beyond politics

    There is no “me” in the team

    There is no “me” in the team

    Although large clinical trial platforms such as RECOVERY and REMAP-CAP have made significant strides in hospitalization of COVID-19 patients from the outset, the lack of large-scale, coordinated efforts to minimize duplication and accelerate results10 An early outpatient study was hinder.


    Ultimately, hydroxychloroquine has no clinical benefit against COVID-1 The efforts of trial staff and the goodwill of patients who volunteered to study should not be undermined, but the lessons learned from this fiasco must inspire us to do better in the next pandem.


    references:

    references:

    Meo SA, Klonoff DC, Akram.


    Meo SA, Klonoff DC, Akram.


    Schwartz IS, Boulware DR, Lee .


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.